Effects of Radiotherapy on Ehrlich’s Ascetic Carcinoma in Swiss Albino Mice: An Experimental Study
Background: Experimental tumors have great importance in modeling, and Ehrlich ascites carcinoma (EAC) is one of the most common tumors. EAC is referred to as an undifferentiated carcinoma and is originally hyperdiploid, has high transplantable capability, no-regression, rapid proliferation, shorter life span, 100% malignancy, and also does not have tumor-specific transplantation antigen. The current concepts that radiotherapy alone or with cancer chemotherapy is administered at a dose to the maximum a patient can tolerate before the onset of severe and even life-threatening toxicity is still in wide clinical use. This study was conducted to evaluate the response of radiotherapy in the treatment of EAC. Materials and Methods: A mouse bearing the tumor strain was taken from our laboratory in the Department of Pathology, IPGMER, Kolkata, where the strain was being maintained serially by inoculation of malignant cells into healthy mice every 8–10 days. In our work, altogether 25 mice were taken for each set of experimental work. They were divided in four groups of 5–10 mice in each group. The various parameters to assess the response of various therapeutic schedules were regression of tumor by decrease in body weight of mice and decrease in abdominal girth; cell count of ascetic fluid and morphological changes of tumor cells after treatment with drugs and to study the percentage viability of the cells. Results: All the mice in Group I gained weight steadily. Mice of Group II were unaffected by single dose whole body radiation and they behaved as mice of Group I. All mice of Group III died within 20–25 days. Conclusion: Cell changes were observed but not as marked. Cell viability was as high as 65% after treatment as compared to tumor control which showed a viability of about 75%.
Ehrlich P, Apolant H. Beobachtungen uber maligne mausetumoren. Berl Klin Wschr 1905;28:871-4.
DeVita VT Jr., Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643-53.
Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel) 2011;3:3279‐330.
Baba AI, Câtoi C. Principles of anticancer therapy. In: Comparative Oncology. Ch. 19. Bucharest, RO: The Publishing House of the Romanian Academy; 2007.
Sugiura K, Schmid FA, Schmid MM. Antitumor activity of cytoxan. Cancer Res 1961;21:1412-20.
DuPre AM, Hempling HG. Osmotic properties of Ehrlich ascites tumor cells during the cell cycle. J Cell Physiol 1978;97:381-96.
Kaleoğlu Ö, İşli N. Ehrlich-Lettre Asit Tümörü. Vol. 40. Tıp Fakültesi Mecmuası; 1977. p. 978-84.
Allen E, Alexander P. An effect of ionizing radiations on the hydrogen bonds in wool. Radiat Res 1961;15:390-9.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Parsons SL, Lang MW, Steele RJ. Malignant ascites: A 2-year review from a teaching hospital. Eur J Surg Oncol 1996;22:237-9.
Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013;31:1592-605.
Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7.
Wang T, Narayanaswamy R, Ren H, Torchilin VP. Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment. Cancer Biol Ther 2016;17:698-707.
Elkhawaga OA, Gebril S, Salah N. Evaluation of anti-tumor activity of metformin against Ehrlich ascites carcinoma in Swiss albino mice. Egypt J Basic Appl Sci 2019;6:116-23.
Wang J, Wang H, Qian H. Biological effects of radiation on cancer cells. Military Med Res 2018;5:20.
Denis V, Couturier AM, Tedim FM, Amélie R, Poirier GG, Fabrice F, et al. DNA damage signalling and repair inhibitors: The long-sought-after Achilles’ heel of cancer. Biomol Ther 2015;5:3204-59.
Lewanski CR, Gullick WJ. Radiotherapy and cellular signalling. Lancet Oncol 2001;2:366-70.
Edimecheva IP, Kisel MA, Shadyro OI, Vlasov AP, Yurkova IL. The damage to phospholipids caused by free radical attack on glycerol and sphingosine backbone. Int J Radiat Biol 1997;71:555-60.
Shao C, Folkard M, Michael BD, Prise KM. Targeted cytoplasmic irradiation induces bystander responses. Proc Natl Acad Sci U S A 2004;101:13495-500.
Bentzen SM. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 2006;6:702-13.
Koontz BF, Verhaegen F, De Ruysscher D. Tumour and normal tissue radiobiology in mouse models: How close are mice to mini-humans? Br J Radiol 2017;90:20160441.
Arnold KM, Flynn NJ, Raben A, Romak L, Yu Y, Adam P, et al. The impact of radiation on the tumor microenvironment: Effect of dose and fractionation schedules. Cancer Growth Metastasis 2018;11:1179064418761639.
Rivina L, Davoren MJ, Schiestl RH. Mouse models for radiation-induced cancers. Mutagenesis 2016;31:491-509.
Carvalho HA, Villar RC. Radiotherapy and immune response: The systemic effects of a local treatment. Clinics (Sao Paulo) 2018;73 Suppl 1:e557s.
Copyright (c) 2020 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Asian Pacific Journal of Health Sciences applies the Creative Commons Attribution (CC-BY) license to published articles. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. Appropriate attribution can be provided by simply citing the original article.